Variable inhibition of high-shear–induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von willebrand release: a randomized, placebo-controlled, clinical trial
- 8 April 2004
- journal article
- clinical trial
- Published by Elsevier in American Heart Journal
- Vol. 147 (4) , 697
- https://doi.org/10.1016/j.ahj.2003.11.003
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blockerPublished by Oxford University Press (OUP) ,2002
- Platelet glycoprotein inhibitors in patients with medically managed acute coronary syndrome: Does the enthusiasm exceed the science?Annals of Emergency Medicine, 2001
- Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary InterventionCirculation, 2001
- Adhesive Interactions of Leukocytes, Platelets, and the Vessel Wall during Hemostasis and InflammationThrombosis and Haemostasis, 2001
- αIIbβ3 and Its Antagonism at the New MillenniumThrombosis and Haemostasis, 2001
- A critical appraisal of platelet glycoprotein IIb/IIIa inhibitionJournal of the American College of Cardiology, 2000
- Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitorsAmerican Heart Journal, 1999
- Platelet aggregation in flow: Differential roles for adhesive receptors and ligandsAmerican Heart Journal, 1998
- Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary interventionThe American Journal of Cardiology, 1995
- Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary InterventionCirculation, 1995